NewAmsterdam Pharma (NASDAQ:NAMS) Raised to “Strong-Buy” at BMO Capital Markets

by · The Markets Daily

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) was upgraded by investment analysts at BMO Capital Markets to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada boosted their target price on NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.42.

Check Out Our Latest Research Report on NAMS

NewAmsterdam Pharma Trading Up 9.0%

Shares of NASDAQ NAMS opened at $32.34 on Monday. The company has a fifty day moving average price of $33.17 and a 200 day moving average price of $32.95. The firm has a market cap of $3.78 billion, a PE ratio of -18.07 and a beta of 0.08. NewAmsterdam Pharma has a 1-year low of $21.14 and a 1-year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. Equities research analysts forecast that NewAmsterdam Pharma will post -1.78 EPS for the current year.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 12.74% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 1.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after purchasing an additional 241,818 shares during the last quarter. Capital World Investors lifted its stake in NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock valued at $350,239,000 after purchasing an additional 161,289 shares during the last quarter. Wellington Management Group LLP increased its position in NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after buying an additional 697,129 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after buying an additional 1,062,359 shares during the last quarter. Finally, Polar Capital Holdings Plc raised its stake in NewAmsterdam Pharma by 15.6% in the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after buying an additional 393,855 shares during the period. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

Recommended Stories